Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

IVERIC bio

DB:O2T
Snowflake Description

Flawless balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
O2T
DB
$39M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The last earnings update was 86 days ago. More info.


Add to Portfolio Compare Print
  • IVERIC bio has significant price volatility in the past 3 months.
O2T Share Price and Events
7 Day Returns
-8.1%
DB:O2T
0.7%
DE Biotechs
1.6%
DE Market
1 Year Returns
-58.3%
DB:O2T
11%
DE Biotechs
9.1%
DE Market
O2T Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
IVERIC bio (O2T) -8.1% -19.8% -21.3% -58.3% -97.1% -97.5%
DE Biotechs 0.7% -1.4% -7.6% 11% 70.7% 8.1%
DE Market 1.6% 4.9% 3.6% 9.1% 10% 20.7%
1 Year Return vs Industry and Market
  • O2T underperformed the Biotechs industry which returned 11% over the past year.
  • O2T underperformed the Market in Germany which returned 9.1% over the past year.
Price Volatility
O2T
Industry
5yr Volatility vs Market
Related Companies

O2T Value

 Is IVERIC bio undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for IVERIC bio. This is due to cash flow or dividend data being unavailable. The share price is €0.85.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for IVERIC bio's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are IVERIC bio's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:O2T PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in USD $1.57
NasdaqGS:ISEE Share Price ** NasdaqGS (2019-10-23) in USD $0.93
Europe Biotechs Industry PE Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 33.48x
Germany Market PE Ratio Median Figure of 406 Publicly-Listed Companies 19.2x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of IVERIC bio.

DB:O2T PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ISEE Share Price ÷ EPS (both in USD)

= 0.93 ÷ 1.57

0.59x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • IVERIC bio is good value based on earnings compared to the Europe Biotechs industry average.
  • IVERIC bio is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does IVERIC bio's expected growth come at a high price?
Raw Data
DB:O2T PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 0.59x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 21 Publicly-Listed Biotechs Companies 1.36x
Germany Market PEG Ratio Median Figure of 263 Publicly-Listed Companies 1.35x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for IVERIC bio, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on IVERIC bio's assets?
Raw Data
DB:O2T PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in USD $2.45
NasdaqGS:ISEE Share Price * NasdaqGS (2019-10-23) in USD $0.93
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.06x
Germany Market PB Ratio Median Figure of 578 Publicly-Listed Companies 1.79x
DB:O2T PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ISEE Share Price ÷ Book Value per Share (both in USD)

= 0.93 ÷ 2.45

0.38x

* Primary Listing of IVERIC bio.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • IVERIC bio is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess IVERIC bio's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. IVERIC bio has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

O2T Future Performance

 How is IVERIC bio expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-99.6%
Expected annual growth in earnings per share.
Earnings growth vs Low Risk Savings
Is IVERIC bio expected to grow at an attractive rate?
  • IVERIC bio's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 0.2%.
Growth vs Market Checks
  • IVERIC bio's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • Unable to compare IVERIC bio's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:O2T Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:O2T Future Earnings per Share Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts -99.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 42.3%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 33.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 12.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:O2T Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:O2T Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 0 1
2019-12-31 0 1
2019-10-26
DB:O2T Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-06-30 -45 62
2019-03-31 -44 64
2018-12-31 -42 63
2018-09-30 0 -45 -51
2018-06-30 207 -50 153
2018-03-31 208 -72 144
2017-12-31 210 -122 114
2017-09-30 215 -141 57
2017-06-30 10 -131 -193
2017-03-31 37 -133 -200
2016-12-31 51 -109 -193
2016-09-30 50 -115 -163

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • IVERIC bio's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Unable to determine if IVERIC bio is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:O2T Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from IVERIC bio Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:O2T Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 -0.76 -0.76 -0.76 1.00
2019-12-31 -1.40 -1.40 -1.40 1.00
2019-10-26
DB:O2T Past Financials Data
Date (Data in USD Millions) EPS *
2019-06-30 1.57
2019-03-31 1.66
2018-12-31 1.70
2018-09-30 -1.40
2018-06-30 4.25
2018-03-31 4.01
2017-12-31 3.18
2017-09-30 1.60
2017-06-30 -5.39
2017-03-31 -5.62
2016-12-31 -5.45
2016-09-30 -4.61

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if IVERIC bio will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess IVERIC bio's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
IVERIC bio has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

O2T Past Performance

  How has IVERIC bio performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare IVERIC bio's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • IVERIC bio has delivered over 20% year on year earnings growth in the past 5 years.
  • IVERIC bio's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • IVERIC bio's 1-year earnings growth is negative, it can't be compared to the Europe Biotechs industry average.
Earnings and Revenue History
IVERIC bio's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from IVERIC bio Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:O2T Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 62.43 22.31
2019-03-31 63.66 23.45
2018-12-31 63.09 23.61
2018-09-30 0.00 -50.57 24.30
2018-06-30 206.65 153.25 24.10
2018-03-31 208.32 144.25 25.61
2017-12-31 209.98 114.21 29.18
2017-09-30 215.30 57.46 36.70
2017-06-30 10.31 -192.50 42.06
2017-03-31 36.85 -200.24 44.70
2016-12-31 50.91 -193.42 50.18
2016-09-30 50.37 -162.79 49.28
2016-06-30 52.15 -141.47 47.66
2016-03-31 25.55 -148.65 49.13
2015-12-31 51.51 -105.72 44.02
2015-09-30 48.41 -101.72 42.61
2015-06-30 84.53 -53.60 41.01
2015-03-31 82.94 -89.45 36.62
2014-12-31 41.26 -116.77 33.39
2014-09-30 39.58 -105.51 27.80
2014-06-30 -132.48 23.15 -6.73
2014-03-31 -71.36 18.82 -2.39
2013-12-31 -57.04 14.21
2013-09-30 -42.25 10.69 2.00
2013-06-30 -29.76 8.79 10.33
2013-03-31 -23.22 7.24 7.56
2012-12-31 -21.63 6.89

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • IVERIC bio made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).
  • IVERIC bio used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • It is difficult to establish if IVERIC bio improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess IVERIC bio's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
IVERIC bio has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

O2T Health

 How is IVERIC bio's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up IVERIC bio's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • IVERIC bio is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • IVERIC bio has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of IVERIC bio's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are -451.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from IVERIC bio Company Filings, last reported 3 months ago.

DB:O2T Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 101.73 0.00 106.89
2019-03-31 113.97 0.00 116.64
2018-12-31 123.96 0.00 131.20
2018-09-30 5.43 125.00 135.21
2018-06-30 17.53 125.00 145.99
2018-03-31 28.08 125.00 154.91
2017-12-31 38.04 125.00 166.97
2017-09-30 43.88 125.00 180.22
2017-06-30 -148.82 125.00 196.44
2017-03-31 -131.66 125.00 227.62
2016-12-31 -94.62 125.00 289.28
2016-09-30 -36.59 125.00 321.16
2016-06-30 14.51 125.00 298.71
2016-03-31 33.22 125.00 292.93
2015-12-31 59.95 125.00 296.59
2015-09-30 83.11 125.00 281.04
2015-06-30 113.78 125.00 449.04
2015-03-31 142.04 125.00 433.29
2014-12-31 128.54 125.00 463.56
2014-09-30 175.90 83.33 408.78
2014-06-30 159.43 83.33 437.23
2014-03-31 207.21 83.33 263.06
2013-12-31 169.72 41.67 210.60
2013-09-30 188.80 41.67 236.08
2013-06-30 27.26 41.67 73.19
2013-03-31 -14.04 12.49 2.20
2012-12-31 -9.53 11.04 4.30
  • IVERIC bio's level of debt (-0.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (52.2% vs -0.2% today).
  • Debt is well covered by operating cash flow (18471.8%, greater than 20% of total debt).
  • IVERIC bio has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess IVERIC bio's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. IVERIC bio has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

O2T Dividends

 What is IVERIC bio's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from IVERIC bio dividends.
If you bought €2,000 of IVERIC bio shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate IVERIC bio's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate IVERIC bio's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:O2T Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.2%
Germany Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:O2T Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31
2019-10-26

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as IVERIC bio has not reported any payouts.
  • Unable to verify if IVERIC bio's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of IVERIC bio's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as IVERIC bio has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess IVERIC bio's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can IVERIC bio afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. IVERIC bio has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

O2T Management

 What is the CEO of IVERIC bio's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Glenn Sblendorio
COMPENSATION $1,411,380
AGE 63
TENURE AS CEO 2.3 years
CEO Bio

Mr. Glenn P. Sblendorio, M.B.A., has been the President of Ophthotech Corporation since February 1, 2017 and has been its Chief Executive Officer since July 1, 2017. Mr. Sblendorio served as Chief Financial Officer and Treasurer of Ophthotech Corporation since April 1, 2016 until April 24, 2017. Mr. Sblendorio served as the Chief Operating Officer and Executive Vice President at Ophthotech Corporation from April 1, 2016 to February 1, 2017. Mr. Sblendorio served as the Strategic Advisor of The Medicines Company since January 1, 2016 until March 31, 2016. He served as President of The Medicines Company from February 21, 2012 to December 2015 and also its Chief Financial Officer from March 17, 2006 to March, 2016 and its Treasurer. He served as Principal Accounting Officer of The Medicines Company and served as its Executive Vice President from March 17, 2006 to February 2012. He served as a Treasurer at Targanta Therapeutics Corp., a subsidiary of Medicines Co. since February 25, 2009. He joined The Medicines Company in March 2006. Mr. Sblendorio served as Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from February 2002 until November 2005. He served as an Executive Vice President and Chief Financial Officer of Oldtech, Inc. from 2002 to November 2005 and also served as its Principal Accounting Officer. Mr. Sblendorio has significant corporate leadership experience, industry knowledge and demonstrated knowledge of financial and financing matters through his prior experience in leading pharmaceutical companies. Mr. Sblendorio served as Senior Vice President of Finance at Eyetech Pharmaceuticals since February 2002. He joined PlayNet Technologies Inc. in August 1996 and served as its Senior Vice President and Chief Financial Officer since August 1996. From July 2000 to February 2002, he served as Senior Vice President of Business Development for The Medicines Company and also served as its Principal Accounting Officer. From 1998 to July 2000, he served as the Chief Executive Officer, Chief Financial Officer and Managing Director of MPM Capital Advisors LLC. From July 1993 to August 1996, Mr. Sblendorio served as Chief Financial Officer of Sony Interactive Entertainment Inc. From October 1981 to July 1993, he served in various positions with the international drug and bio-technology conglomerate, F. Hoffmann La Roche. His pharmaceutical experience also includes 12 years at Hoffmann-La Roche Inc. in a variety of Senior Financial positions, including Chief Financial Officer of Roche Molecular Systems and Head of Finance-Controller for Amgen and Roche Europe. From March 1992 to July 1993, he served as Vice President of Finance of Roche Molecular Systems Inc. From January 1990 to March 1992, Mr. Sblendorio served as a Controller Europe for F. Hoffmann La Roche, Basel. From July 1989 to January 1990, he served as a Vice President of Finance and MIS for Medi Physics Inc. He serves as the Chairman of NuLens, Ltd. He has been a Director of Ophthotech Corporation since May 19, 2017. He has been a Director at Intercept Pharmaceuticals, Inc. since February 18, 2014. He has been an Independent Director of Amicus Therapeutics, Inc. since June 2006. He served as a Director of Ophthotech Corporation since July 2013 until March 2016 and previously served in the same position since July 2013 until January 5, 2016. He served as a Director at The Medicines Company from July 28, 2011 to December 31, 2015 and Targanta Therapeutics Corp. since February 25, 2009. Mr. Sblendorio received B.B.A. in Accounting from Pace University and MBA in Finance from Fairleigh Dickinson University.

CEO Compensation
  • Glenn's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Glenn's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the IVERIC bio management team in years:

2.6
Average Tenure
58
Average Age
  • The tenure for the IVERIC bio management team is about average.
Management Team

David Guyer

TITLE
Executive Chairman
COMPENSATION
$1M
AGE
59

Glenn Sblendorio

TITLE
CEO, President & Director
COMPENSATION
$1M
AGE
63
TENURE
2.3 yrs

Dave Carroll

TITLE
Senior VP
COMPENSATION
$714K
AGE
53
TENURE
2.5 yrs

Keith Westby

TITLE
Senior VP & COO
COMPENSATION
$674K
AGE
44
TENURE
2.8 yrs

Samir Patel

TITLE
Co-Founder and Consultant
AGE
58
TENURE
12.8 yrs

Kathy Galante

TITLE
Vice President of Investor Relations & Corporate Communications

Todd Anderman

TITLE
VP, General Counsel & Corporate Secretary
TENURE
1.8 yrs

Amy Sheehan

TITLE
Senior VP & Chief Human Resources Officer
TENURE
1.8 yrs

Evelyn Harrison

TITLE
Chief Clinical Operations Officer
COMPENSATION
$412K
TENURE
3.8 yrs

Kourous Rezaei

TITLE
Senior VP & Chief Medical Officer
TENURE
3.5 yrs
Board of Directors Tenure

Average tenure and age of the IVERIC bio board of directors in years:

2.4
Average Tenure
63
Average Age
  • The average tenure for the IVERIC bio board of directors is less than 3 years, this suggests a new board.
Board of Directors

Glenn Sblendorio

TITLE
CEO, President & Director
COMPENSATION
$1M
AGE
63
TENURE
2.4 yrs

Axel Bolte

TITLE
Independent Director
COMPENSATION
$91K
AGE
47
TENURE
12.2 yrs

David Guyer

TITLE
Executive Chairman
COMPENSATION
$1M
AGE
59
TENURE
12.8 yrs

Jane Pritchett Henderson

TITLE
Independent Director
COMPENSATION
$162K
AGE
53
TENURE
1.8 yrs

Adrienne Graves

TITLE
Lead Independent Director
COMPENSATION
$47K
AGE
66

David Cheresh

TITLE
Member of Translational Scientific Advisory Board

Rakesh Jain

TITLE
Member of Translational Scientific Advisory Board
AGE
69

Cal Roberts

TITLE
Independent Director
AGE
67
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
13. May 19 Buy Glenn Sblendorio Individual 10. May 19 10. May 19 25,000 €1.32 €32,912
X
Management checks
We assess IVERIC bio's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. IVERIC bio has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

O2T News

Simply Wall St News

O2T Company Info

Description

IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD). It is also developing High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitors for the treatment of GA secondary to dry AMD and other age-related retinal diseases, such as wet AMD and idiopathic polypoidal choroidal vasculopathy. The company has a license agreement with the University of Florida Research Foundation (UFRF) and the University of Pennsylvania for the development and commercialization of novel adeno-associated virus (AAV) gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP); and Best disease and other bestrophinopathies. It also has a research agreement with the University of Massachusetts Medical School to utilize the minigene therapy approach to create AAV gene therapy product candidates targeting Leber Congenital Amaurosis type 10 and STGD1; and to evaluate various AAV gene delivery methods for potential application in the eye. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was founded in 2007 and is headquartered in New York, New York.

Details
Name: IVERIC bio, Inc.
O2T
Exchange: DB
Founded: 2007
$34,857,551
41,562,695
Website: http://ivericbio.com
Address: IVERIC bio, Inc.
One Penn Plaza,
19th Floor,
New York,
New York, 10119,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ISEE Common Stock Nasdaq Global Select US USD 25. Sep 2013
DB O2T Common Stock Deutsche Boerse AG DE EUR 25. Sep 2013
Number of employees
Current staff
Staff numbers
33
IVERIC bio employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/10/26 21:47
End of day share price update: 2019/10/23 00:00
Last estimates confirmation: 2019/10/14
Last earnings filing: 2019/08/01
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.